What's Left In $400M Skinny Label Row? A Lot, Court Says <https://www.law360.com/health/articles/2273496?nl_pk=6422bbc2-a823-4be5-9a9f-132770eb1771&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2024-12-16&read_main=1&nlsidx=0&nlaidx=12>
By Theresa Schliep A number of key issues remain live in the $400 million fight between Teva Pharmaceuticals and GlaxoSmithKline over whether the generic-drug maker induced healthcare providers to infringe the brand-name company's heart drug patent, including the availability of a new trial, a Delaware federal judge has said. Opinion attached | Read full article » <https://www.law360.com/health/articles/2273496?nl_pk=6422bbc2-a823-4be5-9a9f-132770eb1771&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2024-12-16&read_more=1&nlsidx=0&nlaidx=12> | Save to favorites » <https://www.law360.com/health/articles/2273496?nl_pk=6422bbc2-a823-4be5-9a9f-132770eb1771&utm_source=newsletter&utm_medium=email&utm_campaign=health&utm_content=2024-12-16&read_later=1&nlsidx=0&nlaidx=12>
